BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

407.83 20.58 +5.31%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a

BeOne Medicines Ltd. - Sponsored ADR (ONC) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a EV/FCF of 27.1×. Over the past ten years it has ranged from −149× (June 2025) to 159× (September 2025); the current reading is higher than 91% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 32.4× —
FY2024 −27.1× —
FY2023 −8.9× —
FY2022 −10.4× —
FY2021 −11.9× —
FY2020 −12.4× —
FY2019 −11.0× —
FY2018 −9.4× —
FY2017 −77.0× —
FY2016 −5.4× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 25.3× 18.91%
Jun 2026 21.3× (20.83%)
Mar 2026 26.9× (17.00%)
Dec 2025 32.4× (49.96%)
40 more quarters

Against its own ten years

Low −149× High 159×
Ten-year median −9.5×
Current reading's percentile 91

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ONC